{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:41:19Z","timestamp":1778715679909,"version":"3.51.4"},"reference-count":170,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,2,2]],"date-time":"2009-02-02T00:00:00Z","timestamp":1233532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antiplatelet therapy is a mainstay in the treatment of patients who have undergone percutaneous coronary intervention (PCI). Although the 2007 PCI treatment guidelines were published by the American College of Cardiology, the American Heart Association, and the Society for Cardiovascular Angiography and Interventions, new clinical evidence has emerged, expanding our understanding of antiplatelet use and potentially affecting the treatment guidelines. For example, clinical trial results prompted a Science Advisory to recommend that dual therapy with aspirin and clopidogrel be used for longer periods\u2014up to 1 year in patients who receive bare metal stents and at least 1 year in patients receiving drug\u2010eluting stents. New trial results have also emerged regarding the use of glycoprotein IIb\/IIIa antagonists such as abciximab, eptifibatide, and tirofiban. This article reviews the current recommendations for antiplatelet therapy in PCI patients, recent trial results, newly developed agents, ongoing clinical trials, and the future direction of antiplatelet therapy in patients who undergo PCI. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ccd.22021","type":"journal-article","created":{"date-parts":[[2009,2,2]],"date-time":"2009-02-02T20:09:56Z","timestamp":1233605396000},"page":"579-597","source":"Crossref","is-referenced-by-count":17,"title":["Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA\/ACC\/SCAI guidelines and beyond"],"prefix":"10.1002","volume":"74","author":[{"given":"Marc","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,5,26]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.188208"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000264509.36234.51"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.187998"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.1-2-132"},{"key":"e_1_2_7_6_2","first-page":"87","article-title":"Drug review\u2013Clopidogrel","volume":"1","author":"Chambers S","year":"2004","journal-title":"Drugs Context"},{"key":"e_1_2_7_7_2","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS\u20102","volume":"2","author":"ISIS\u20102 (Second International Study of Infarct Survival) Collaborative Group","year":"1988","journal-title":"Lancet"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.11.3194"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199921040-00007"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.69.5.377"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2411"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.04.005"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.14.1759"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi620"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.25.2829"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442503"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013404"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)02335-9"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000091201.39590.CB"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1309\/0G1PEJ00J8KP8357"},{"key":"e_1_2_7_25_2","first-page":"1","article-title":"Genetic factors underlying differential blood platelet sensitivity to inhibitors","volume":"57","author":"Rozalski M","year":"2005","journal-title":"Pharmacol Rep"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.07.056"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.07.041"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.10.079"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.01.094"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl275"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.06.065"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000130846.46168.03"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.12.034"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.10.042"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.04.014"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02656.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.08.002"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.04.090"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.667741"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1159\/000096988"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl489"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.06.049"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.4.553"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2006.05.006"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.03.054"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.10.064"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.10.047"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.01.044"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.10.030"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.18.2051"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-08-0503"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000124581.18191.15"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2003.10.039"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.08.036"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.09.013"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.12.036"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.06.003"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.11.012"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.6.591"},{"key":"e_1_2_7_60_2","first-page":"793","article-title":"Is transport with platelet GP IIb\/IIIa inhibition for primary percutaneous coronary intervention more efficient than on\u2010site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results","volume":"64","author":"Dobrzycki S","year":"2006","journal-title":"Kardiol Pol"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.02.074"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.12.077"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-006-5708-0"},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.01.071"},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.05.003"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60450-4"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.04.057"},{"key":"e_1_2_7_68_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052711"},{"key":"e_1_2_7_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.08.002"},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.20735"},{"key":"e_1_2_7_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2005.06.003"},{"key":"e_1_2_7_72_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1160\/TH05-10-0700","article-title":"Anti\u2010thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: An ex vivo human study","volume":"95","author":"Lev EI","year":"2006","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.027"},{"key":"e_1_2_7_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.01.027"},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpcardio0706"},{"key":"e_1_2_7_76_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.107.144576"},{"key":"e_1_2_7_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.04.035"},{"key":"e_1_2_7_78_2","first-page":"487","article-title":"High\u2010dose, single\u2010bolus eptifibatide: A safe and cost\u2010effective alternative to conventional glycoprotein IIb\/IIIa inhibitor use for elective coronary interventions","volume":"18","author":"Fischell TA","year":"2006","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_7_79_2","first-page":"521","article-title":"Bolus\u2010only platelet glycoprotein IIb\u2010IIIa inhibition during percutaneous coronary intervention","volume":"18","author":"Marmur JD","year":"2006","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_7_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.04.009"},{"key":"e_1_2_7_81_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.joc60034"},{"key":"e_1_2_7_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.12.084"},{"key":"e_1_2_7_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.04.029"},{"key":"e_1_2_7_84_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-005-0870-4"},{"key":"e_1_2_7_85_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.085456"},{"key":"e_1_2_7_86_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.20334"},{"key":"e_1_2_7_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.10.054"},{"key":"e_1_2_7_88_2","first-page":"296","article-title":"The impact of GP IIb\/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients","volume":"17","author":"Lavi S","year":"2005","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_7_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.05.007"},{"key":"e_1_2_7_90_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.502815"},{"key":"e_1_2_7_91_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2006.047696"},{"key":"e_1_2_7_92_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_2_7_93_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.740324"},{"key":"e_1_2_7_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.053"},{"key":"e_1_2_7_95_2","first-page":"U677","article-title":"The DISPERSE2 trial: Safety, tolerability and preliminary efficacy of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel in patients with non\u2010ST segment elevation acute coronary syndrome","volume":"112","author":"DISPERSE\u20102\u2010Investigators","year":"2005","journal-title":"Circulation"},{"key":"e_1_2_7_96_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi754"},{"key":"e_1_2_7_97_2","first-page":"698","article-title":"AZD6140 exerts greater inhibition of platelet aggregation than clopidogrel in patients with stable atherosclerotic disease or unstable coronary disease","volume":"114","author":"Storey RF","year":"2006","journal-title":"Circulation"},{"key":"e_1_2_7_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.058"},{"key":"e_1_2_7_99_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200312000-00005"},{"key":"e_1_2_7_100_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000181762.31694.da"},{"key":"e_1_2_7_101_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01891.x"},{"key":"e_1_2_7_102_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-013052"},{"key":"e_1_2_7_103_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.crd.0000188033.11188.8e"},{"key":"e_1_2_7_104_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-006-8670-y"},{"key":"e_1_2_7_105_2","doi-asserted-by":"publisher","DOI":"10.1080\/00207230500120294"},{"key":"e_1_2_7_106_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01372.x"},{"key":"e_1_2_7_107_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi684"},{"key":"e_1_2_7_108_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-005-0044-0"},{"key":"e_1_2_7_109_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpcardio0728"},{"key":"e_1_2_7_110_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02498.x"},{"key":"e_1_2_7_111_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02655.x"},{"key":"e_1_2_7_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.051"},{"key":"e_1_2_7_113_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000147228.29325.F9"},{"key":"e_1_2_7_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.09.008"},{"key":"e_1_2_7_115_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-008-6121-z"},{"key":"e_1_2_7_116_2","doi-asserted-by":"publisher","DOI":"10.1080\/14017430410024324"},{"key":"e_1_2_7_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2005.12.024"},{"key":"e_1_2_7_118_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.5852"},{"key":"e_1_2_7_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2005.09.052"},{"key":"e_1_2_7_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2005.03.038"},{"key":"e_1_2_7_121_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-869523"},{"key":"e_1_2_7_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01713-2"},{"key":"e_1_2_7_123_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.180944"},{"key":"e_1_2_7_124_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8183.2006.00181.x"},{"key":"e_1_2_7_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.01.034"},{"key":"e_1_2_7_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.09.067"},{"key":"e_1_2_7_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.04.050"},{"key":"e_1_2_7_128_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000047060.60595.CC"},{"key":"e_1_2_7_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(03)94372-7"},{"key":"e_1_2_7_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.06.064"},{"key":"e_1_2_7_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.090"},{"key":"e_1_2_7_132_2","first-page":"e166","article-title":"ACC\/AHA\/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention)","volume":"113","author":"Smith SC","year":"2006","journal-title":"Circulation"},{"key":"e_1_2_7_133_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1160\/TH07-09-0562","article-title":"Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study","volume":"99","author":"Angiolillo DJ","year":"2008","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.09.087"},{"key":"e_1_2_7_135_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2007.06.012"},{"key":"e_1_2_7_136_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000160869.75810.98"},{"key":"e_1_2_7_137_2","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.105.559088","article-title":"Absorption, metabolization, and antiplatelet effects of 300\u2010, 600\u2010, and 900\u2010mg loading doses of clopidogrel: Results of the ISAR\u2010CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial","volume":"112","author":"von Beckerath N","year":"2005","journal-title":"Circulation"},{"key":"e_1_2_7_138_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000161383.06692.D4"},{"key":"e_1_2_7_139_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000157138.02645.11"},{"key":"e_1_2_7_140_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2007.00013.x"},{"key":"e_1_2_7_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.08.060"},{"key":"e_1_2_7_142_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00354.x"},{"key":"e_1_2_7_143_2","first-page":"S_815\u2010a\u2010","article-title":"Abstract 3999: Baseline Proton Pump Inhibitor Use is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial","volume":"118","author":"Dunn SP","year":"2008","journal-title":"Circulation"},{"key":"e_1_2_7_144_2","doi-asserted-by":"crossref","first-page":"S_815\u2010","DOI":"10.1161\/circ.118.suppl_18.S_815","article-title":"Abstract 3998: Proton pump inhibitors effect on clopidogrel effectiveness: The clopidogrel medco outcomes study","volume":"118","author":"Aubert RE","year":"2008","journal-title":"Circulation"},{"key":"e_1_2_7_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2005.04.025"},{"key":"e_1_2_7_146_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.20798"},{"key":"e_1_2_7_147_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi293"},{"key":"e_1_2_7_148_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706816"},{"key":"e_1_2_7_149_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.05.058"},{"key":"e_1_2_7_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05775-0"},{"key":"e_1_2_7_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05059-5"},{"key":"e_1_2_7_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.04.019"},{"key":"e_1_2_7_153_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.03.023"},{"key":"e_1_2_7_154_2","first-page":"O\u2010S\u2010004","volume-title":"Late breaking clinical trial: Bivalirudin with and without eptifibatide for elective stenting: A pharmacodynamic study of platelet reactivity in relation to the occurrence of periprocedural myocardial infarction (The CLEAR\u2010PLATELETS\u20102 study). 2007","author":"Gurbel PA","year":"2007"},{"key":"e_1_2_7_155_2","first-page":"550","article-title":"The coronary artery revascularisation in diabetes (CARDia) trial: A prospective, randomised comparison of optimal coronary angioplasty with use of stenting and abciximab recommended versus up to date coronary artery bypass grafting in patients with diabetes mellitus suitable for either intervention","volume":"89","author":"Kapur A","year":"2003","journal-title":"Heart"},{"key":"e_1_2_7_156_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-008-0625-1"},{"key":"e_1_2_7_157_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.03.029"},{"key":"e_1_2_7_158_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.747642"},{"key":"e_1_2_7_159_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.04.012"},{"key":"e_1_2_7_160_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60422-5"},{"key":"e_1_2_7_161_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0706859"},{"key":"e_1_2_7_162_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.791061"},{"key":"e_1_2_7_163_2","first-page":"250","article-title":"Cangrelor AstraZeneca","volume":"2","author":"Chattaraj SC","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_7_164_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G120"},{"key":"e_1_2_7_165_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)85149-9"},{"key":"e_1_2_7_166_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.11.014"},{"key":"e_1_2_7_167_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.06.001"},{"key":"e_1_2_7_168_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.2.225"},{"key":"e_1_2_7_169_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi887"},{"key":"e_1_2_7_170_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01294.x"},{"key":"e_1_2_7_171_2","first-page":"49","article-title":"Results of a multinational randomized, double\u2010blind, placebo\u2010controlled study of a novel thrombin receptor antagonist (SCH 530348) in percutaneous coronary intervention","author":"Moliterno DJ","year":"2007","journal-title":"J Am Coll Cardiol"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.22021","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.22021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T14:11:06Z","timestamp":1697465466000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.22021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,26]]},"references-count":170,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1002\/ccd.22021"],"URL":"https:\/\/doi.org\/10.1002\/ccd.22021","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,26]]}}}